AOD-9604

What is AOD-9604?

AOD-9604 (Advanced Obesity Drug) is a synthetic peptide corresponding to the C-terminal fragment of human growth hormone, specifically amino acids 177–191, with an additional tyrosine residue at the N-terminus. Developed by Metabolic Pharmaceuticals in Australia, it isolates the fat-metabolizing properties of growth hormone without its diabetogenic or growth-promoting effects.

The mechanism involves stimulation of lipolysis and inhibition of lipogenesis in adipose tissue through the beta-3 adrenergic receptor pathway. Unlike full-length growth hormone, AOD-9604 does not compete for the GH receptor, does not stimulate IGF-1, and does not affect insulin sensitivity or blood glucose. This selectivity makes it unique in the metabolic research space.

Preclinical studies demonstrated significant fat reduction in obese Zucker rats without changes in lean body mass [1]. Phase 2 clinical trials showed statistically significant weight loss versus placebo [3]. The compound received GRAS (Generally Recognized As Safe) status from the FDA in 2010 for use as a food supplement ingredient, an unusual regulatory distinction for a peptide compound.

Mechanism of Action

AOD-9604's fat-metabolizing effects operate through a distinct pathway from full-length growth hormone:

Beta-3 Adrenergic Receptor Pathway

AOD-9604 stimulates lipolysis through activation of the beta-3 adrenergic receptor (ADRB3) on adipocytes. This receptor is primarily expressed in visceral and brown adipose tissue and, when activated, triggers the cAMP-PKA signaling cascade that phosphorylates hormone-sensitive lipase (HSL), driving triglyceride breakdown into free fatty acids and glycerol [1].

Lipogenesis Inhibition

Beyond promoting fat breakdown, AOD-9604 simultaneously inhibits lipogenesis — the formation of new fat. Research has shown that the peptide reduces the activity of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), the rate-limiting enzymes in de novo lipogenesis. This dual action (promoting fat breakdown while preventing fat formation) distinguishes AOD-9604 from agents that only address one side of the equation [2].

Selectivity Over Full-Length GH

The critical advantage of AOD-9604 is what it does NOT do. Unlike full-length growth hormone, the fragment does not bind the GH receptor, does not elevate IGF-1 levels, does not affect insulin sensitivity, does not alter blood glucose, and does not promote longitudinal bone growth. This selectivity eliminates the diabetogenic risks and acromegalic concerns associated with exogenous GH administration.

Cartilage Regeneration

More recent research has identified unexpected chondroprotective effects. AOD-9604 appears to stimulate proteoglycan synthesis in articular cartilage, leading to investigation of its potential in osteoarthritis management. This property is unrelated to its fat-metabolizing mechanism and may represent a separate receptor interaction.

Dosing Protocol

AOD-9604 is administered on an empty stomach. Food intake, particularly fats and carbohydrates, may reduce the peptide's efficacy by suppressing the lipolytic response.

Reconstitution Guide

Reconstitute lyophilized AOD-9604 with bacteriostatic water. The peptide dissolves readily without excessive mixing.

1. Remove the plastic cap from the AOD-9604 vial and wipe the rubber stopper with an alcohol swab. Allow to dry.
2. Draw 2 mL of bacteriostatic water into a sterile syringe. For a 5 mg vial, this yields a concentration of 2,500 mcg/mL.
3. Insert the needle through the rubber stopper at a slight angle. Inject the water slowly against the inner wall of the vial — do not spray directly onto the peptide powder.
4. Allow the vial to sit for 1–2 minutes. Gently roll the vial between your palms if needed. Do not shake or vortex.
5. The solution should be completely clear and colorless. Discard if you observe any cloudiness, particulate matter, or discoloration.

Injection Technique

AOD-9604 is administered via subcutaneous (SubQ) injection. Abdominal injection is preferred for fat-loss protocols.

1. Clean the injection site with an alcohol swab and allow it to air dry completely (approximately 30 seconds). Common sites: lower abdomen (2 inches from the navel), upper thigh, or upper arm.
2. Draw the dose. Insert the needle into the vial through the rubber stopper. Invert the vial and draw the calculated number of units slowly. Tap the syringe to move any air bubbles to the top, then push them out gently.
3. Pinch the skin at the injection site to create a fold of subcutaneous tissue. Insert the needle at a 45-degree angle in a quick, smooth motion. Release the skin fold.
4. Inject slowly. Depress the plunger steadily over 5–10 seconds. Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a clean swab if needed.

Storage & Stability

AOD-9604 follows standard peptide storage guidelines. Proper handling is essential to maintain potency throughout the cycle.

Side Effects & Considerations

AOD-9604 has demonstrated a very favorable safety profile in both preclinical studies and Phase 2 human trials, with adverse event rates similar to placebo.

Commonly Reported

• Mild injection site reactions — redness or minor irritation, resolving quickly.
• Headache — transient, reported infrequently.

Key Safety Features

• No effects on blood glucose, insulin levels, IGF-1, or cortisol in clinical studies [3].
• No anti-hGH antibody formation observed in trials.
• Received FDA GRAS status in 2010, indicating safety for food supplement use.
• Must be administered in a fasted state; food may reduce efficacy.
• No growth-promoting effects — safe for individuals where GH receptor stimulation would be contraindicated.

Stacking Protocols

AOD-9604 is sometimes combined with other peptides in body composition research protocols.

AOD-9604 + Ipamorelin + CJC-1295 (Body Composition Stack)

This combination targets fat loss through AOD-9604's direct lipolytic action while supporting lean mass through GH secretagogue-mediated growth hormone elevation. The three peptides work through entirely independent pathways with no receptor competition.

Lifestyle Factors

Research suggests the following complementary practices may optimize AOD-9604's fat-metabolizing effects:

• Fasting window: Extending the morning fasted window may enhance lipolysis. Injecting AOD-9604 first thing in the morning and delaying breakfast by 30–60 minutes may optimize fat mobilization.
• Exercise timing: Light to moderate fasted cardio after morning injection may compound the lipolytic effect, as the mobilized fatty acids are more readily oxidized during exercise.
• Diet composition: A moderate caloric deficit with adequate protein (1.2–1.6 g/kg) supports fat loss while preserving lean tissue.
• Sleep: 7–9 hours nightly. Sleep deprivation elevates cortisol, which promotes visceral fat storage — directly counteracting AOD-9604's mechanism.

Related Peptides

Researchers studying AOD-9604 often investigate these related compounds:

Literature & Citations

1. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001;142(12):5182-5189. PubMed
2. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(5):274-278. PubMed
3. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Invest. 2013;36(3):174-180. PubMed
4. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. PubMed
5. Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-E526. PubMed